Anadys Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Anadys Pharmaceuticals, Inc.
The intellectual property, also held by Eureka, may offer a new pathway for treating relapsed MM patients. Sorrento inks cancer partnerships with Karolinska Institutet and Mayo Clinic.
The WHO indicates that several claim applications have been made under the COVAX no-fault lump-sum compensation program for COVID-19 vaccines. It remains to be seen how the scheme may apply to countries like India, which is also expected to take a call on indemnity to vaccine makers.
Moderna’s mRNA COVID-19 vaccine has been cleared in India for restricted emergency use, with expectations building for a go-ahead for Pfizer/BioNTech’s jab too, though it will be important to see how the country deals with the contentious issue of indemnity to vaccine makers.
Amryt’s birch bark extract oleogel-S10 for Epidermolysis Bullosa patients might become only the third botanical drug to clear the FDA.